A jury handed Thousand Oaks-based Amgen a win in a long-running patent dispute against two of its competitors Feb. 25 over an alternative to its cholesterol treatment Repatha. The decision in a Delaware court upholds a previous jury ruling in 2016 against a competing drug developed by French multinational Sanofi and New York-based Regeneron called…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
